|
|
|
Slide 4. PEGASYS® maintains consistent plasma
levels over a week
|
|
•PEGASYS® is associated with antiviral coverage that is
sustained throughout the weekly dosing interval.
|
|
•After one subcutaneous injection of PEGASYS® 180 μg,
the serum drug level reaches a maximum concentration of 14.2 ng/mL (bottom
curve).1 Unlike the drug concentration-time curve for unpegylated
interferons2, serum concentrations of PEGASYS® are
constant and sustained throughout the week.
|
|
•Until steady state is reached (5 to 9 weeks), serum concentrations
more than double and are constant and sustained throughout the week.3
After steady state is reached, further drug accumulation does not occur (the
amount of PEGASYS® eliminated from the body equals the amount
entering via administration). The concentration-time curve for the week 9
injection (not shown) would be similar to that for the week 48 injection (top
curve).3
|
|
•Once the entire treatment course with PEGASYS® 180 μg
once weekly has been completed, the serum concentration levels slowly
descend; complete elimination of the drug occurs within 50 to 60 days
post-treatment.3
|
|
|
|
1. Algranati N, et al.
Hepatology 1999; 30(Suppl 2): 190A
|
|
2. Koslowski A, et al.
BioDrugs 2001; 15: 419
|
|
3. Modi M, et al. Hepatology
2000; 32(Suppl): 394
|
|
|
